| Lastacaft (U.S.N.L.M.) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dosing | 1 drop daily | ||||||||
| Chem Specs | alcaftadine 0.25% | ||||||||
| Quantities | 3 mL | ||||||||
| Cost | 252.00/3ml | ||||||||
| Class | H1, H2, H4 receptor antagonist¹ | ||||||||
| Action | Competitive H1 receptor inhibitor. Mast cell stabilizer. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. |
||||||||
| Usage | Indicated for the treatment of itching associated with allergic conjunctivitis. | ||||||||
| BAK may be absorbed in soft contact lenses. Contact lenses may be inserted 10 minutes after administration. Contraindications |
Hypersensitivity to any component of the product.. |
Pediatric use |
Safety and efficacy not established for patients under 2 years of age. |
Pregnancy |
No maternal or embryofetal toxicity at clinically relevant doses |
in animal studies.
| BAK .005% |
|
¹ Gallois-Bernos & Thurmond
One study found less itch and better chemosis relief with alcaftadine than olopatadine.
Ackerman, D’Ambrosio, Greiner, Villanueva, Ciolino, and Hollander